RxDoctor Payments Data

Sumer Walker, APRN

Family · Lewes, DENPI 1154987279

Payments from drug & device makers

$1,726in general payments, 2019–2025

Across 39 payments — averaging $44.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$607
  • Lilly USA, LLC$219
  • Menarini Silicon Biosystems, Inc.$171
  • AstraZeneca$137
  • Kyowa Kirin, Inc.$126
  • Phathom Pharmaceuticals, Inc.$123
  • plus $343 from 7 others

What the payments were for

  • Food & beverage$1,726100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,726 in reported general payments places this provider in the 75th percentile of 523 family providers in Delaware.

See all family providers in Delaware

Medicare billing

Part B allowed, 2024
$22,452
Medicare patients
69
Services billed
486

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide29$35,000
MounjaroTirzepatide28$32,659
Xtampza ErOxycodone Myristate30$18,726
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen179$6,006
Oxycodone Hcl207$4,126
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen77$1,899
Morphine Sulfate ErMorphine Sulfate58$1,834
Lidocaine14$1,533
Gabapentin90$1,335
Morphine Sulfate22$891
Tizanidine Hcl46$872
Cyclobenzaprine Hcl58$843
Tramadol Hcl ErTramadol Hcl14$665
Bupropion XlBupropion Hcl27$616
Hydromorphone Hcl26$612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$607$35,00029 claims
Lilly USA, LLCMounjaro$219$32,65928 claims
Collegium Pharmaceutical, Inc.Xtampza Er$68$18,72630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 523 family providers in Delaware.

Other family in Lewes

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →